Privately-held biotech Allegro Ophthalmics said today that its Del Mar Phase IIb stage 2 trial met its primary endpoint. The study assessed Luminate as a sequential therapy or combo therapy in 80 patients with diabetic macular edema. The San Juan Capistrano, Calif.-based company’s Luminate integrin peptide therapy treats neovascular retinal diseases by targeting integrin receptors, […]
